RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia
Technologies, Inc. (“Liquidia”), a late-stage clinical
biopharmaceutical company focused on improving the performance of
medicine by precisely engineering drug particles, today announced the
appointment of Jeri Thomas as Senior Vice President, Commercial. Ms.
Thomas will have responsibility for developing and leading Liquidia’s
commercial plans, with initial focus on LIQ861, an inhaled dry powder
formulation of treprostinil currently being evaluated in a pivotal Phase
3 safety trial (INSPIRE) for the treatment of pulmonary arterial
hypertension (PAH).

“Jeri brings an extensive background in building and leading commercial
organizations,” stated Neal Fowler, Chief Executive Officer of Liquidia.
“As we look to advance LIQ861 for the treatment of PAH, having her
expertise will be critical to the development and leadership of our
commercialization strategy. She is a leader within the industry and we
are excited to have her onboard.”

Most recently, Ms. Thomas was Senior Vice President, Strategic Group
Planning at Harrison and Star, a global healthcare marketing agency.
Prior to that, she served as Senior Vice President of the Surgical &
Perioperative Care Business Unit at The Medicines Company where she led
the global commercialization of IONSYS®, the first drug-device
combination product for acute postoperative pain. Prior to The Medicines
Company, Ms. Thomas was at Janssen Pharmaceuticals (a Johnson & Johnson
company) where she held various senior leadership positions including
Vice President, Market Strategy & Access for Latin America, Vice
President, New Business and New Product Planning, and Director of
Marketing, Analgesic Franchise. She has also held management positions
at Bristol-Myers Squibb and Hoffman-La Roche Pharmaceuticals. Ms. Thomas
obtained her Master of Business Administration in a dual program from
the McDonough School of Business at Georgetown University and ESADE
Business School in Barcelona, Spain. She received a Bachelor of Science
in Health Planning and Administration from Penn State University.

“I am impressed and excited with the team’s commitment to improving the
quality of life for those living with PAH,” commented Ms. Thomas. “The
innovative design of LIQ861 to enable deep-lung delivery and to safely
deliver higher doses into the lungs has the potential to overcome the
limitations of current nebulized therapies. Liquidia is positioned for
the next stage of growth with LIQ861 in late-stage development and I
look forward to playing a role in its success.”

ABOUT LIQUIDIA TECHNOLOGIES

Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical
biopharmaceutical company that is focused on improving the performance
of medicines by precisely engineering drug particles. Liquidia’s
proprietary PRINT®
technology is designed to improve the safety, efficacy or route of
administration of a wide range of therapies by engineering uniform drug
particles in a wide variety of compositions, sizes and shapes.
Currently, Liquidia is developing two of its own product candidates
using PRINT® particles: LIQ861 for the treatment of PAH and LIQ865 for
the treatment of local post-operative pain. Liquidia’s lead product
candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial
(INSPIRE), is designed to improve the therapeutic profile of
treprostinil by enhancing deep-lung delivery and achieving higher dose
levels than current inhaled therapies by using a convenient, disposable
dry powder inhaler. LIQ865, for which Liquidia has recently completed a
U.S. Phase 1b clinical trial, is designed to deliver sustained-release
particles of bupivacaine, a non-opioid anesthetic, to treat local
post-operative pain. In addition to developing our own product
candidates, Liquidia collaborates with leading pharmaceutical companies
to apply its PRINT® technology across existing drugs, new chemical
entities and biologics. For more information, please visit www.liquidia.com.